In the US, Interferon Alfa-2b (interferon alfa-2b systemic) is a member of the drug class antineoplastic interferons and is used to treat Angioblastoma, Condylomata Acuminata, Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Follicular Lymphoma, Hairy Cell Leukemia, Hepatitis B, Hepatitis C, Idiopathic Thrombocytopenic Purpura, Kaposi's Sarcoma and Melanoma.

US matches:

• Interferon alfa-2b
• Interferon Alfa-2b Injection Solution
• Interferon Alfa-2b Powder for Injection

Scheme

USAN

ATC (Anatomical Therapeutic Chemical Classification)

L03AB05,S01AD05

CAS registry number (Chemical Abstracts Service)

0099210-65-8

Chemical Formula

C860-H1353-N229-O255-S9

Molecular Weight

19269

Therapeutic Categories

Antineoplastic agent

Antiviral agent: Treatment of hepatitis

Biological response modifier, BRM

Immunomodulator

Foreign Names

• Interferonum alfa-2b (Arg-23; His-34) (Latin)
• Interferon alfa-2b (Arg-23; His-34) (German)
• Interféron alfa-2b (Arg-23; His-34) (French)
• Interferón alfa-2b (Arg-23; His-34) (Spanish)

Generic Names

• Interferon Alfa-2b (OS: USAN, BAN)
• Interferon Alfa-2b (Genetical Recombination) (OS: JAN)
• IFNalpha2b (IS)
• r-IFN-Alfa-2b (IS)
• Sch 30500 (IS)
• Interferon Alfa-2 Concentrated Solution (PH: BP 2016)
• Interferon Alfa-2b (Genetical Recombination) (PH: JP XVI)

Brand Names

• Alfaferone
  Alfa Wassermann, Lebanon
• Allergoferon [+ Loratadine]
  Firn M, Russian Federation
• Allergoferon Beta [+ Betamethasone]
  Firn M, Russian Federation
• Alphaferoi
  Akber Brothers, Pakistan
• An Da Fen
  Anke Biotechnology Group, China
• An Fu Long
  HuaLiDa Biotechnology, China
• An Te Fu
  Neptunus Pharmaceutical, China
• Anferon
  Atco, Pakistan
• Bioferon
  Bio Sidus, Thailand; Sidus, Argentina; Sidus, Paraguay; Sidus, Uruguay; Instituto Sidus, Lebanon
• Blauferon-B
  Pharmatec, Pakistan
• Blauferon-B 3 MUI
  Blausiegel, Uruguay
• Cell-aid
  Werrick, Pakistan
• Ceron-alfa
  Biocare, Pakistan
• Chang Sheng De Jia
  Changchun Institute of Biological Products, China
• Chang Sheng Fu Kang
  Changchun Institute of Biological Products, China
• Enduferon
  Heber, Philippines
• Genferon [+ Taurine]
  ZAO "BIOKAD", Georgia
• Green-alpha
  Genesis, Pakistan
• Heberon-alpha
  Macter, Pakistan
• Inf 3Mui
  Bago, Paraguay
• Inrec
  Clausen, Uruguay
• Intefen
  NovaMed, Pakistan
• Inter 2B
  Biosidus, Argentina
• Interferon Alfa 2b Cassara
  Promofarma, Uruguay; Varifarma, Argentina
• Interferon Alfa 2b V y T Farma
  V y T Farma, Paraguay
• Interferon Alfa-2b Humano Recombinante Bago
  Laboratorio Bago, Chile
• Interferonas alfa-2b
  Sicor Biotech, Lithuania
• Interlong
  Hepacare, Pakistan; Neptunus Pharmaceutical, China
• Intron A
  Bayer Schering, Iran; M.S.D., Portugal; Merck Canada, Canada; Merck Sharp & Dohme, Australia; Merck Sharp & Dohme, Bosnia & Herzegowina; Merck Sharp & Dohme, Hong Kong; Merck Sharp & Dohme, Croatia (Hrvatska); Merck Sharp & Dohme, Mexico; Merck Sharp & Dohme, New Zealand; Merck Sharp & Dohme, Poland; Merck Sharp & Dohme, Romania; Merck Sharp & Dohme, Slovenia; MSD, Japan; MSD Belgium, Belgium; MSD Belgium, Luxembourg; MSD Merck Sharp & Dohme, Germany; Schering, United Arab Emirates; Schering, Egypt; Schering, Iraq; Schering, Jordan; Schering, Qatar; Schering, Saudi Arabia; Schering, United States; Schering, Yemen; Schering-Plough, Bahrain; Schering-Plough, Indonesia; Schering-Plough, Israel; Schering-Plough, Kuwait; Schering-Plough, Lebanon; Schering-Plough, Philippines; Schering-Plough, Serbia; Schering-Plough, Russian Federation; Schering-Plough, Syria; Schering-Plough, Venezuela; Schering-Plough, South Africa; Schering-Plough Labo, Macedonia
• Intron A (Merck Sharp & Dohme
  China MSD, China
• Intron A
  Merck Sharp & Dohme Pharma Singapore, Singapore
• Intron A 10 Mio IE
  MSD, Switzerland
• Intron A 30 Mio IE
  MSD, Switzerland
• Intron A 60 Mio IE
  MSD, Switzerland
• Intron A Multi-Dose
  Schering-Plough, Taiwan
• Intron A Redipen
  Merck Sharp & Dohme, Australia
• Intron Redipen
  Schering-Plough, Venezuela
• IntronA
  Merck, Iceland; Merck Sharp & Dohme, Chile; Merck Sharp & Dohme, United Kingdom; Merck Sharp & Dohme, Greece; Merck Sharp & Dohme, Lithuania; MSD, Czech Republic; MSD, Denmark; MSD, Finland; MSD, Ireland; MSD, Norway; MSD, Sweden; MSD, Slovakia; Schering-Plough, Italy; Schering-Plough, Lithuania
• Introna
  Merck Sharp & Dohme, Cyprus; Merck Sharp & Dohme, Estonia; Merck Sharp & Dohme, Spain
• Intron-A
  Atco, Pakistan; Merck Sharp & Dohme, Mexico; Merck Sharp & Dohme, Malaysia; MSD Merck Sharp & Dohme, Turkey
• IntronA 18 millió NE
  MSD Pharma, Hungary
• IntronA 18 Mio. I.E.
  Merck Sharp & Dohme, Austria
• IntronA 18 Mio. I.E./3ml
  Merck Sharp & Dohme, Austria
• IntronA 25 Mio. I.E./2,5ml
  Merck Sharp & Dohme, Austria
• IntronA 30 millió NE
  MSD Pharma, Hungary
• IntronA 30 Mio. I.E.
  Merck Sharp & Dohme, Austria
• IntronA 60 millió NE
  MSD Pharma, Hungary
• IntronA 60 Mio. I.E.
  Merck Sharp & Dohme, Austria
• Jie Fu
  HuaLiDa Biotechnology, China
• Kaifu
  Kawin Technologie, China
• Kalferon
  Kalbe, Indonesia
• Laferon
  Rubikon, Georgia
• Lai Fu Long
  Beisheng Medicine Industry Hansheng Pharmaceutical, China
• Li Fen Neng
  Hayao Pharmaceutical Group Holding, China
• Li Ya Mei
  Hayao Pharmaceutical Group Holding, China
• Longhuanuo
  Binhai Xinbao, China
• Ophthalmoferon [+ Diphenhydramine]
  ZAO, Georgia
• Peg-Intron
  Schering-Plough, Oman
• Realdiron
  Sicor Biotech, Lithuania; Sicor Biotech, Serbia
• Rebetron [+ Ribavirin]
  Schering-Plough, Kuwait
• Refergen
  Sicor Biotech, Lithuania
• Reliferon
  Ambica, Philippines
• Ruferon-Rn
  Rubikon, Georgia
• Urifron
  Probiomed, Mexico
• Urifrón
  Probiomed, Dominican Republic; Probiomed, Guatemala; Probiomed, Honduras; Probiomed, El Salvador
• Viferon
  Feron, Georgia
• Viraferon
  Fulford, India; Schering-Plough, Lithuania
• Yi Sheng
  Kawin Technologie, China
• You Ni Long
  Tongyong Tongmeng Pharmaceutical, China

Glossary

Further information on drug naming conventions: International Nonproprietary Names.